1147-98-4

Basic information

• Product Name: 5-chloro-N-(4-chlorophenyl)-2-hydroxy-benzamide
• Synonyms: 5-chloro-N-(4-chlorophenyl)-2-hydroxy-benzamide
• CAS NO: 1147-98-4
• Molecular Formula: C₁₃H₉Cl₂NO₂
• Molecular Weight: 282.12
• Mol File: 1147-98-4.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 363°Cat760mmHg
• Flash Point: 173.3°C
• Appearance: /
• Density: 1.479g/cm³
• Vapor Pressure: 8.89E-06mmHg at 25°C
• Refractive Index: 1.685
• CAS DataBase Reference: 5-chloro-N-(4-chlorophenyl)-2-hydroxy-benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 5-chloro-N-(4-chlorophenyl)-2-hydroxy-benzamide(1147-98-4)
• EPA Substance Registry System: 5-chloro-N-(4-chlorophenyl)-2-hydroxy-benzamide(1147-98-4)

Safety Data

• Hazardous Substances Data: 1147-98-4(Hazardous Substances Data)

Usage

General Description

5-chloro-N-(4-chlorophenyl)-2-hydroxy-benzamide is a chemical compound with the molecular formula C13H9Cl2NO2. It is a derivative of benzanilide and contains chlorine and hydroxyl functional groups. 5-chloro-N-(4-chlorophenyl)-2-hydroxy-benzamide is used in the field of medicinal chemistry and pharmaceutical research as it exhibits potential biological activities. Its structure and properties make it a promising candidate for drug development, particularly in the treatment of various diseases and conditions. Additionally, it is also employed in chemical and biochemical research as a reference compound for studying the structure-activity relationships of related molecules.

InChI:InChI=1/C13H9Cl2NO2/c14-8-1-4-10(5-2-8)16-13(18)11-7-9(15)3-6-12(11)17/h1-7,17H,(H,16,18)

Upstream product

• 87-17-2 salicylanilide 
• 71-43-2 benzene 
• 15216-81-6 5-chloro-2-hydroxybenzoyl chloride 
• 106-47-8 4-chloro-aniline 

Downstream Products

• 20972-98-9 6-chloro-3-(4-chloro-phenyl)-2,3-dihydro-benzo[e][1,3]oxazin-4-one 
• 17893-02-6 4-chloro-2-(4-chlorophenylcarbamoyl)phenyl acetate 
• 1121627-43-7 (S)-4-chloro-2-(4-chlorophenylcarbamoyl)phenyl 2-(benzyloxycarbonylamino)-3-methylbutanoate 
• 1121627-40-4 4-chloro-2-(4-chlorophenylcarbamoyl)phenyl 2-(benzyloxycarbonylamino)acetate 
• 1403607-21-5 4-chloro-2-(4-chlorophenylcarbamoyl)phenyl 4-(trifluoromethyl)benzoate 
• 1219818-86-6 4-chloro-2-(4-chlorophenylcarbamoyl)phenyl undecylcarbamate 
• 1219818-85-5 4-chloro-2-(4-chlorophenylcarbamoyl)phenyl decylcarbamate 
• 1219818-84-4 4-chloro-2-(4-chlorophenylcarbamoyl)phenyl nonylcarbamate 
• 1219818-83-3 4-chloro-2-(4-chlorophenylcarbamoyl)phenyl octylcarbamate 
• 1219818-82-2 4-chloro-2-(4-chlorophenylcarbamoyl)phenyl heptylcarbamate 
• 1219818-81-1 4-chloro-2-(4-chlorophenylcarbamoyl)phenyl hexylcarbamate 
• 1219818-80-0 4-chloro-2-(4-chlorophenylcarbamoyl)phenyl pentylcarbamate 
• 1261296-06-3 (S)-4-chloro-2-(4-chlorophenylcarbamoyl)phenyl 2-acetamido-3-phenylpropanoate 
• 1219818-79-7 4-chloro-2-(4-chlorophenylcarbamoyl)phenyl butylcarbamate 

Relevant articles and documents

Application of niclosamide and analogs as small molecule inhibitors of Zika virus and SARS-CoV-2 infection

Zika virus has emerged as a potential threat to human health globally. A previous drug repurposing screen identified the approved anthelminthic drug niclosamide as a small molecule inhibitor of Zika virus infection. However, as antihelminthic drugs are generally designed to have low absorption when dosed orally, the very limited bioavailability of niclosamide will likely hinder its potential direct repurposing as an antiviral medication. Here, we conducted SAR studies focusing on the anilide and salicylic acid regions of niclosamide to improve physicochemical properties such as microsomal metabolic stability, permeability and solubility. We found that the 5-bromo substitution in the salicylic acid region retains potency while providing better drug-like properties. Other modifications in the anilide region with 2′-OMe and 2′-H substitutions were also advantageous. We found that the 4′-NO2 substituent can be replaced with a 4′-CN or 4′-CF3 substituents. Together, these modifications provide a basis for optimizing the structure of niclosamide to improve systemic exposure for application of niclosamide analogs as drug lead candidates for treating Zika and other viral infections. Indeed, key analogs were also able to rescue cells from the cytopathic effect of SARS-CoV-2 infection, indicating relevance for therapeutic strategies targeting the COVID-19 pandemic.

Synthesis of substituted 2,3-dihydro-4H-1,3-benzoxazin-4-ones and their biological activities.

-